RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Amgen (AMGN) Receives a Buy From Piper Sandler
Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $335
Bernstein Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Navigating 14 Analyst Ratings For Amgen
Cantor Fitzgerald Reiterates Overweight on Amgen, Maintains $405 Price Target
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $383
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
Amgen Analyst Ratings
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $335 to $381
DBS Maintains Amgen(AMGN.US) With Buy Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies Remains a Buy on Amgen (AMGN)
Amgen Analyst Ratings
Truist Financial Downgrades Amgen(AMGN.US) to Hold Rating, Announces Target Price $333
Morgan Stanley Adjusts Price Target on Amgen to $319 From $316